Society ❯ Health Issues ❯ Obesity Epidemic

Treatment Options

Long-term Effects GLP-1 Drugs Innovative Therapies Pharmaceutical Innovations

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.